Douglas Muir

Douglas Muir

Auto-generated profile, based on publicly available information

Douglas Muir

James Cook University Hospital, Middlesbrough, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2025 in New England Journal of Medicine
Verified
Journal Article
Closed access
RKRajesh K Kharbanda
Rajesh K Kharbanda
JKJames Kennedy
James Kennedy
ZJZahra Jamal
Zahra Jamal
MDMatthew Dodd
Matthew Dodd
RERichard Evans
Richard Evans
BIBHF PROTECT-TAVI Investigators
BHF PROTECT-TAVI Investigators
Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence of stroke. We conducted a randomized, controlled trial across 33 centers in the United Kingdom. We randomly assigned 7635 participants with aortic stenosis in a 1:1 ratio to undergo TAVI with a CEP device (CEP group) or TAVI without a CEP device (control group). The primary outcome was stroke within 72 hours after TAVI or before discharge from the hospital (if discharge occurred sooner). A total of 3815 participants were assigned to the CEP group and 3820 to the control group. A primary-outcome event occurred in 81 of 3795 participants (2.1%) in the CEP group and in 82 of 3799 participants (2.2%) in the control group (difference, -0.02 percentage points; 95% confidence interval, -0.68 to 0.63; P = 0.94). Disabling stroke occurred in 47 participants (1.2%) in the CEP group and in 53 (1.4%) in the control group. Death occurred in 29 participants (0.8%) in the CEP group and in 26 (0.7%) in the control group. Overall access-site complications appeared to be similar in the two groups (8.1% in the CEP group and 7.7% in the control group). A total of 24 serious adverse events occurred in 22 of 3798 participants (0.6%) in the CEP group, and 13 serious adverse events occurred in 13 of 3803 participants (0.3%) in the control group. Among participants undergoing TAVI, routine use of CEP did not decrease the incidence of stroke within 72 hours. (Funded by the British Heart Foundation and Boston Scientific; BHF PROTECT-TAVI ISRCTN Registry number, ISRCTN16665769.).

30 March 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DFDerk Frank
Derk Frank
EDEric Durand
Eric Durand
SLSandra Lauck
Sandra Lauck
DMDouglas F Muir
Douglas F Muir
MSMark Spence
Mark Spence
GMGemma McCalmont
Gemma McCalmont
There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries. This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety. Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%). Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety. BENCHMARK: streamlined transcatheter aortic valve implantation (TAVI) pathway with retained safety. CCU, coronary care unit; ICU, intensive care unit; GW, general ward; IMC, intermediate care; PPM, permanent pacemaker. *Includes patients with available data on LoS only.

1 January 2026 in European Heart Journal - Valvular and Structural Heart Disease
Verified
Journal Article
Open access
PDF file
SLSandra B Lauck
Sandra B Lauck
BKBettina Højberg Kirk
Bettina Højberg Kirk
GMGemma McCalmont
Gemma McCalmont
DFDerk Frank
Derk Frank
MRMarjo de Ronde-Tilmans
Marjo de Ronde-Tilmans
DMDouglas F Muir
Douglas F Muir
Background: Transcatheter options are increasingly available for the treatment of valvular heart disease. The role of the clinical valve co-ordinator is ideally positioned to improve access to care, quality of outcomes, and patient experiences, contribute to efficiencies, and support the growing number of heart valve centres. International societies and guidelines recommend the inclusion of the clinical valve co-ordinator in multidisciplinary Heart Teams to support patients, contribute unique expertise to team-based care, and help programmes expand access to care. The role of the clinical valve co-ordinator is unevenly adopted in Europe. Aims: To provide guidance on developing, implementing, and sustaining the role of clinical valve co-ordinators to support patients and programmes. Methods and results: We outline a comprehensive framework of the competencies and professional development aligned with the needs of patients with aortic, mitral, and tricuspid disease, discuss requirements for infrastructure and successful organizational integration in valvular heart disease teams and programmes, and propose preliminary indicators to measure role impact and address the current gap in evidence to guide role development across diverse regions. The clinical valve co-ordinator plays a vital role as a central member of the multidisciplinary team to support the care requirements of people with complex valvular heart disease in the rapidly evolving clinical context of treatment options and management strategies. Conclusion: The document provides a roadmap for the development, implementation, and evaluation of a pan-European initiative to improve the delivery of valvular heart disease services and optimize the experience of care of patients and their family.

1 November 2020 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Closed access
PMPeter J McCartney
Peter J McCartney
HEHany Eteiba
Hany Eteiba
AMAnnette Maznyczka
Annette Maznyczka
MMMargaret McEntegart
Margaret McEntegart
JGJohn P Greenwood
John P Greenwood
CBColin Berry
Colin Berry
Efficacy and Mechanism Evaluation Volume: 7, Issue: 5, Published in November 2020

10 June 2025 in Interventional Cardiology: Reviews, Research, Resources
Verified
Journal Article
Open access
PDF file
SMSamuel Joseph McGrath
Samuel Joseph McGrath
HMHolly Morgan
Holly Morgan
DMDouglas Muir
Douglas Muir
DHDavid Hildick-Smith
David Hildick-Smith
Background: Interventional cardiology (IC) is a competitive and oversubscribed subspecialty. The UK cardiology programme is currently in a state of transition of curricula, and concerns have arisen about the impact of this change on the standard of training. This study aimed to provide a snapshot of UK IC training at present. Methods: A 68-question survey was disseminated through the British Cardiovascular Interventional Society mailing list in November 2023 to all UK intervention trainees across both curricula. Questions included procedural numbers, exposure to adjunct techniques and confidence in the transition to consultancy. Results: The survey was completed by 60 participants, providing a response rate of 38% for training grades. A total of 87% of participants were men, and 78% remained on the 2010 curriculum. For the 2010 curriculum trainees, the median number of first-operator percutaneous coronary intervention was 101–200 in their first year. Confidence levels were higher for radial (98%) than femoral (62%) access. A total of 83% felt comfortable or confident using intravascular lithotripsy (83%) compared with 23% for rotational atherectomy. Comfort was higher with intravascular ultrasound (82%) compared with optical coherence tomography (53%). Half felt unprepared for consultancy, citing insufficient procedural experience. To address this, 65% plan to extend training with a fellowship year. Overall, 72% rated the programme as excellent or good, and 10% as poor. Conclusion: While many trainees report a positive experience with UK IC training, several areas need improvement, including procedural volume and requirement for extended training. Moving forward, it will be crucial to monitor the impact of the 2022 curriculum on IC training.